Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S. Vescarelli E, et al. Among authors: megiorni f. J Exp Clin Cancer Res. 2020 Jan 2;39(1):3. doi: 10.1186/s13046-019-1490-7. J Exp Clin Cancer Res. 2020. PMID: 31898520 Free PMC article.
MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.
Anastasiadou E, Messina E, Sanavia T, Mundo L, Farinella F, Lazzi S, Megiorni F, Ceccarelli S, Pontecorvi P, Marampon F, Di Gioia CRT, Perniola G, Panici PB, Leoncini L, Trivedi P, Lenzi A, Marchese C. Anastasiadou E, et al. Among authors: megiorni f. Cells. 2021 Mar 1;10(3):519. doi: 10.3390/cells10030519. Cells. 2021. PMID: 33804458 Free PMC article.
MiR-200c-3p maintains stemness and proliferative potential in adipose-derived stem cells by counteracting senescence mechanisms.
Anastasiadou E, Ceccarelli S, Messina E, Gerini G, Megiorni F, Pontecorvi P, Camero S, Onesti MG, Trivedi P, Faenza M, Coscioni E, Nicoletti GF, Napoli C, Marchese C. Anastasiadou E, et al. Among authors: megiorni f. PLoS One. 2021 Sep 17;16(9):e0257070. doi: 10.1371/journal.pone.0257070. eCollection 2021. PLoS One. 2021. PMID: 34534238 Free PMC article.
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C. Camero S, et al. Among authors: megiorni f. J Cancer Res Clin Oncol. 2019 Jan;145(1):137-152. doi: 10.1007/s00432-018-2774-6. Epub 2018 Oct 24. J Cancer Res Clin Oncol. 2019. PMID: 30357520 Free PMC article.
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.
Ceccarelli S, Megiorni F, Bellavia D, Marchese C, Screpanti I, Checquolo S. Ceccarelli S, et al. Among authors: megiorni f. Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019. Stem Cells Int. 2019. PMID: 30723507 Free PMC article. Review.
OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence.
Megiorni F, Camero S, Pontecorvi P, Camicia L, Marampon F, Ceccarelli S, Anastasiadou E, Bernabò N, Perniola G, Pizzuti A, Benedetti Panici P, Tombolini V, Marchese C. Megiorni F, et al. Cancers (Basel). 2021 Mar 25;13(7):1519. doi: 10.3390/cancers13071519. Cancers (Basel). 2021. PMID: 33806232 Free PMC article.
73 results